Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Japanese Sales Practices at Pharmaceutical Firms Report 2016 - Current Sales Activities, Regulations, Issues, and Suggested Methodologies - Research and Markets

Research and Markets
Posted on: 01 Nov 16

Research and Markets has announced the addition of the "Japanese Sales Practices at Pharmaceutical Firms ver2016" report to their offering.

This report discusses about the general sales practices at pharmaceutical firms in Japan. The readers will understand about the current sales activities, regulations, issues, and suggested methodologies.

The number of MR in Japan in 2015 was 64,135. At all type of companies; domestic pharmaceutical companies, foreign companies, and Contract Sales Organizations (CSO), the number of MR had been increasing until 2013, but it turned to decrease from 2014.

Among developed nations, Japan follows the United States in terms of number of MR. However, at the same time, when we look at the number of physicians per number of MR, the United States has approximately thirteen (physicians/MR), while Japan has below five, so we see considerable gap and an outstanding issue in terms of productivity.

While people see less productivity in sales activities, the number of MR still remain quite large. The unique MR skillset and the Japanese old employment system, which emphasized long-term employment, created a situation that renders both internal transfer and dismissal difficult. Also, the pharmaceutical industry has enjoyed considerably high profits, meaning that even bearing these fixed labor costs in mind, there was no sense of urgency to firms' economic viability.

Key Topics Covered:

1. Summary

2. Scope Discussed

3. Medical Representative

4. Number of MR

5. Number of MR by Company

6. Number of MR by Country

7. Is the number of MR in Japan reasonable?

8. Why So Many MR in Japan?

9. Regulations Concerning the Sale of Pharmaceuticals

10. Financial Contributions to Medical Institutions, Universities, and Physicians

11. Curbing Extreme Sales Tactics

12. Theoretical Underpinnings of Business & HR Strategy at Foreign Firms

13. Declining MR's Presence

14. Future Outlook

For more information about this report visit

View source version on

Business Wire

Last updated on: 01/11/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.